fenofibrate has been researched along with Renal Insufficiency, Chronic in 16 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter, randomized study evaluated the short-term efficacy and safety profile of fenofibric acid (FA) + rosuvastatin (R) combination therapy for improving lipid parameters in patients with stage 3 CKD and mixed dyslipidemia." | 5.17 | A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. ( Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA, 2013) |
| "For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF." | 2.84 | Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. ( Applegate, WB; Cushman, W; Doumas, M; Lovato, L; Mottle, A; Nylen, E; Papademetriou, V; Punthakee, Z; Tsioufis, C, 2017) |
| " We suggest that Pema may be an effective and safe treatment for hypertriglyceridemia in CKD patients." | 1.91 | Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study. ( Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Hernandez-Arroyo, CF | 1 |
| Kanduri, SR | 1 |
| Justiniano, R | 1 |
| Martinez-Pitre, PJ | 1 |
| Velez, JCQ | 1 |
| Iwasaki, M | 1 |
| Suzuki, H | 1 |
| Umezawa, Y | 1 |
| Koshida, T | 1 |
| Saito, M | 1 |
| Fukuda, H | 1 |
| Takahara, H | 1 |
| Matsuzaki, K | 1 |
| Suzuki, Y | 1 |
| Horinouchi, Y | 1 |
| Murashima, Y | 1 |
| Yamada, Y | 1 |
| Yoshioka, S | 1 |
| Fukushima, K | 1 |
| Kure, T | 1 |
| Sasaki, N | 1 |
| Imanishi, M | 1 |
| Fujino, H | 1 |
| Tsuchiya, K | 1 |
| Shinomiya, K | 1 |
| Ikeda, Y | 1 |
| Yen, CL | 1 |
| Fan, PC | 1 |
| Lin, MS | 1 |
| Lee, CC | 1 |
| Tu, KH | 1 |
| Chen, CY | 1 |
| Hsiao, CC | 1 |
| Hsu, HH | 1 |
| Tian, YC | 1 |
| Chang, CH | 1 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| Maas, R | 1 |
| Mieth, M | 1 |
| Titze, SI | 1 |
| Hübner, S | 1 |
| Fromm, MF | 1 |
| Kielstein, JT | 1 |
| Schmid, M | 1 |
| Köttgen, A | 1 |
| Kronenberg, F | 1 |
| Krane, V | 1 |
| Hausknecht, B | 1 |
| Eckardt, KU | 1 |
| Schneider, MP | 1 |
| Katsiki, N | 1 |
| Mikhailidis, DP | 1 |
| Banach, M | 1 |
| Weinstein, DL | 1 |
| Williams, LA | 1 |
| Carlson, DM | 1 |
| Kelly, MT | 1 |
| Burns, KM | 1 |
| Setze, CM | 1 |
| Lele, A | 1 |
| Stolzenbach, JC | 1 |
| Saito, T | 1 |
| Matsunaga, A | 1 |
| Ito, K | 1 |
| Nakashima, H | 1 |
| Márk, L | 1 |
| Dani, G | 1 |
| Papademetriou, V | 1 |
| Lovato, L | 1 |
| Tsioufis, C | 1 |
| Cushman, W | 1 |
| Applegate, WB | 1 |
| Mottle, A | 1 |
| Punthakee, Z | 1 |
| Nylen, E | 1 |
| Doumas, M | 1 |
| Kaysen, GA | 1 |
| Sousa, AA | 1 |
| Kronit, HS | 1 |
| Neves, Fde A | 1 |
| Amato, AA | 1 |
| Tanaka, Y | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Chin-Kanasaki, M | 1 |
| Sakaguchi, M | 1 |
| Sugimoto, T | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Lewis, D | 1 |
| Wanner, C | 1 |
| Paul, S | 1 |
| Mohan, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease[NCT00680017] | Phase 3 | 280 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
High-density lipoprotein cholesterol (HDL-C) was measured in milligrams/deciliter (mg/dL). (NCT00680017)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| ABT-335 Plus Rosuvastatin | 16.9 |
| Rosuvastatin | 7.8 |
Triglycerides were measured in milligrams/deciliter. (NCT00680017)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 Plus Rosuvastatin | -38.0 |
| Rosuvastatin | -22.4 |
4 reviews available for fenofibrate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Fatty Acids, Omega-3; Fenofibrate; Humans; Hyd | 2019 |
Topics in lipoprotein glomerulopathy: an overview.
Topics: Apolipoprotein E2; Apolipoproteins E; Fenofibrate; Founder Effect; Humans; Hypertriglyceridemia; Kid | 2014 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
2 trials available for fenofibrate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Chole | 2013 |
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofib | 2017 |
10 other studies available for fenofibrate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Improvement in Kidney Function after Discontinuation of Fenofibrate in Outpatient Nephrology Consultation for Chronic Kidney Disease.
Topics: Creatinine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Kidn | 2022 |
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Topics: Bezafibrate; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Renal Insufficiency; Rena | 2023 |
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
Topics: Animals; Creatinine; Fenofibrate; Fibrosis; Kidney; Mice; PPAR alpha; Renal Insufficiency, Chronic; | 2023 |
Fenofibrate Delays the Need for Dialysis and Reduces Cardiovascular Risk Among Patients With Advanced CKD.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Fenofibrate; Hear | 2021 |
Drugs linked to plasma homoarginine in chronic kidney disease patients-a cross-sectional analysis of the German Chronic Kidney Disease cohort.
Topics: Adolescent; Adult; Aged; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Fenof | 2020 |
Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients.
Topics: Cardiovascular Diseases; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoli | 2017 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.
Topics: Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; | 2009 |
Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis.
Topics: Animals; Anti-Inflammatory Agents; Base Sequence; Cells, Cultured; Chemokine CCL2; Dietary Fats; Dis | 2011 |
Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2012 |
Fenofibrate can increase serum creatinine levels in renal insufficiency.
Topics: Contraindications; Creatinine; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Rena | 2006 |